Business Context and Reporting Period
Company: Armata Pharmaceuticals, Inc. (ARMP)
Filing Type: Form 8-K (Current Report)
Date of Report: March 19, 2026
Reporting Period Context: The filing addresses the fourth quarter and full-year period ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a delay in the release of these financial results rather than a disclosure of the figures themselves.
Material Changes
Delay in Financial Reporting: The Company announced a delay in the announcement of its financial results for the fourth quarter and full-year ended December 31, 2025. No specific financial variances were disclosed in this document.
Guidance, Outlook, and Management Commentary
Corporate Update: The Company issued a press release (Exhibit 99.1) providing a corporate update alongside the announcement of the reporting delay.
Regulatory Status: The information furnished in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any registration statement.
Investor Verification Checklist
- Verify the specific reasons for the delay in financial reporting by reviewing the full text of the press release (Exhibit 99.1).
- Monitor for the rescheduled date for the release of Q4 and full-year 2025 financial results.
- Review the "corporate update" details provided in the press release for any operational changes or strategic shifts.
- Confirm if the delay impacts the Company's compliance with exchange listing standards or debt covenants.